Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov​.

WHO urges artemisinin resistance testing

January / February 2014 | Volume 13, Issue 1

The WHO recently released its 2013 world report on malaria that urges countries to follow standard procedures in routinely testing how well malaria treatments are working, to enhance comparison of national data and allow quicker reaction to the buildup of drug resistance in malaria-causing parasites.

"Continuous monitoring of the efficacy of and resistance to antimalarial drugs is critical, in order to inform treatment policy and ensure early detection of changing patterns of resistance," the WHO report notes. This practice "can help to detect early changes in Plasmodium falciparum sensitivity to artemisinin."

The study reiterates that to contain the risk of artemisinin resistance, health authorities in nine countries permitting artemisinin-based monotherapies should ban the practice and ensure the drug is given only in combination with other malaria treatments to preserve its effectiveness over time.

More Information

• Access the full World Malaria Report 2013 and country profiles from the World Health Organization (WHO).
• Access additional malaria information, resources and funding opportunities from Fogarty, NIH and more.

To view Adobe PDF files, download current, free accessible plug-ins from Adobe's website.